Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group
Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study g...
Gespeichert in:
| Veröffentlicht in: | Medical and pediatric oncology 1992, Vol.20 (6), p.497-505 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 505 |
|---|---|
| container_issue | 6 |
| container_start_page | 497 |
| container_title | Medical and pediatric oncology |
| container_volume | 20 |
| creator | van der Does-Van den Berg, Anna Bartram, Claus R. Basso, Giuseppe Benoit, Yves C. M. Biondi, Andrea Debatin, Klaus-Michael Haas, Oskar A. Harbott, Jochen Kamps, Willem A. Köller, Ursula Lampert, Fritz Ludwig, Wolf-Dieter Niemeyer, Charlotte M. van Wering, Elisabeth R. |
| description | Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French‐American‐British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B‐ALL and T‐ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/mpo.2950200603 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73317367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73317367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5023-14ee2ded012c3ab8001a94ca3af997fe1743b842472a9f0c6d2b71902c5983d53</originalsourceid><addsrcrecordid>eNqFUU1v1DAQjRCoLIUrNySrqhBIzeKPeBMf24oWpF3KAQTiYs06k66pE6d2UtgfxX_E-6FWnDiNZua9Nx8vy14yOmWU8ndt76dcScopnVHxKJswqma5Yuz742xCqapyJgV_mj2L8SdNuSqrg-yAFUJKTifZn4XtbAuOBLwdbcAWuyGSxgcyrJDUFq47H208IcZBjLaxBgbruxMCXU3wDty4zYlvtoQhIAwbjU3BrKyrV97XBMw4IHHrtl_5ZRIarCEOxxtsLZA3p_P5W2K7rcDR2cWCNNBatz4ixvseQxpwh-Q6-LF_nj1pwEV8sY-H2deL91_OP-Tzq8uP56fz3KRHiJwViLzGmjJuBCwrShmowoCAJt3fICsLsawKXpQcVEPNrObLkinKjVSVqKU4zF7vdPvgb0eMg25tNOgcdOjHqEshWClmZQJOd0ATfIwBG92H9M6w1ozqjT86-aMf_EmEV3vlcdli_QDfGZL6x_s-RAOuCdAZG-9hhWRKzDYLqh3sl3W4_s9Qvfh89c8K-Y5r44C_77kQbnS6qJT626dLLSmjP6Rk-kz8BeFmugc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73317367</pqid></control><display><type>article</type><title>Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>van der Does-Van den Berg, Anna ; Bartram, Claus R. ; Basso, Giuseppe ; Benoit, Yves C. M. ; Biondi, Andrea ; Debatin, Klaus-Michael ; Haas, Oskar A. ; Harbott, Jochen ; Kamps, Willem A. ; Köller, Ursula ; Lampert, Fritz ; Ludwig, Wolf-Dieter ; Niemeyer, Charlotte M. ; van Wering, Elisabeth R.</creator><creatorcontrib>van der Does-Van den Berg, Anna ; Bartram, Claus R. ; Basso, Giuseppe ; Benoit, Yves C. M. ; Biondi, Andrea ; Debatin, Klaus-Michael ; Haas, Oskar A. ; Harbott, Jochen ; Kamps, Willem A. ; Köller, Ursula ; Lampert, Fritz ; Ludwig, Wolf-Dieter ; Niemeyer, Charlotte M. ; van Wering, Elisabeth R.</creatorcontrib><description>Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French‐American‐British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B‐ALL and T‐ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley‐Liss, Inc.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950200603</identifier><identifier>PMID: 1435520</identifier><identifier>CODEN: MPONDB</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>acute lymphoblastic leukemia ; BFM-family ; Biological and medical sciences ; Child ; children ; Chromosome Aberrations ; classification ; diagnosis ; Hematologic and hematopoietic diseases ; Humans ; Immunophenotyping ; International Cooperation ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Multicenter Studies as Topic - standards ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Ploidies ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - classification ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><ispartof>Medical and pediatric oncology, 1992, Vol.20 (6), p.497-505</ispartof><rights>Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1993 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5023-14ee2ded012c3ab8001a94ca3af997fe1743b842472a9f0c6d2b71902c5983d53</citedby><cites>FETCH-LOGICAL-c5023-14ee2ded012c3ab8001a94ca3af997fe1743b842472a9f0c6d2b71902c5983d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950200603$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950200603$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4519365$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1435520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Does-Van den Berg, Anna</creatorcontrib><creatorcontrib>Bartram, Claus R.</creatorcontrib><creatorcontrib>Basso, Giuseppe</creatorcontrib><creatorcontrib>Benoit, Yves C. M.</creatorcontrib><creatorcontrib>Biondi, Andrea</creatorcontrib><creatorcontrib>Debatin, Klaus-Michael</creatorcontrib><creatorcontrib>Haas, Oskar A.</creatorcontrib><creatorcontrib>Harbott, Jochen</creatorcontrib><creatorcontrib>Kamps, Willem A.</creatorcontrib><creatorcontrib>Köller, Ursula</creatorcontrib><creatorcontrib>Lampert, Fritz</creatorcontrib><creatorcontrib>Ludwig, Wolf-Dieter</creatorcontrib><creatorcontrib>Niemeyer, Charlotte M.</creatorcontrib><creatorcontrib>van Wering, Elisabeth R.</creatorcontrib><title>Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French‐American‐British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B‐ALL and T‐ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley‐Liss, Inc.</description><subject>acute lymphoblastic leukemia</subject><subject>BFM-family</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>children</subject><subject>Chromosome Aberrations</subject><subject>classification</subject><subject>diagnosis</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>International Cooperation</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Multicenter Studies as Topic - standards</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Ploidies</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - classification</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAQjRCoLIUrNySrqhBIzeKPeBMf24oWpF3KAQTiYs06k66pE6d2UtgfxX_E-6FWnDiNZua9Nx8vy14yOmWU8ndt76dcScopnVHxKJswqma5Yuz742xCqapyJgV_mj2L8SdNuSqrg-yAFUJKTifZn4XtbAuOBLwdbcAWuyGSxgcyrJDUFq47H208IcZBjLaxBgbruxMCXU3wDty4zYlvtoQhIAwbjU3BrKyrV97XBMw4IHHrtl_5ZRIarCEOxxtsLZA3p_P5W2K7rcDR2cWCNNBatz4ixvseQxpwh-Q6-LF_nj1pwEV8sY-H2deL91_OP-Tzq8uP56fz3KRHiJwViLzGmjJuBCwrShmowoCAJt3fICsLsawKXpQcVEPNrObLkinKjVSVqKU4zF7vdPvgb0eMg25tNOgcdOjHqEshWClmZQJOd0ATfIwBG92H9M6w1ozqjT86-aMf_EmEV3vlcdli_QDfGZL6x_s-RAOuCdAZG-9hhWRKzDYLqh3sl3W4_s9Qvfh89c8K-Y5r44C_77kQbnS6qJT626dLLSmjP6Rk-kz8BeFmugc</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>van der Does-Van den Berg, Anna</creator><creator>Bartram, Claus R.</creator><creator>Basso, Giuseppe</creator><creator>Benoit, Yves C. M.</creator><creator>Biondi, Andrea</creator><creator>Debatin, Klaus-Michael</creator><creator>Haas, Oskar A.</creator><creator>Harbott, Jochen</creator><creator>Kamps, Willem A.</creator><creator>Köller, Ursula</creator><creator>Lampert, Fritz</creator><creator>Ludwig, Wolf-Dieter</creator><creator>Niemeyer, Charlotte M.</creator><creator>van Wering, Elisabeth R.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1992</creationdate><title>Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group</title><author>van der Does-Van den Berg, Anna ; Bartram, Claus R. ; Basso, Giuseppe ; Benoit, Yves C. M. ; Biondi, Andrea ; Debatin, Klaus-Michael ; Haas, Oskar A. ; Harbott, Jochen ; Kamps, Willem A. ; Köller, Ursula ; Lampert, Fritz ; Ludwig, Wolf-Dieter ; Niemeyer, Charlotte M. ; van Wering, Elisabeth R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5023-14ee2ded012c3ab8001a94ca3af997fe1743b842472a9f0c6d2b71902c5983d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>acute lymphoblastic leukemia</topic><topic>BFM-family</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>children</topic><topic>Chromosome Aberrations</topic><topic>classification</topic><topic>diagnosis</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>International Cooperation</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Multicenter Studies as Topic - standards</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Ploidies</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - classification</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>van der Does-Van den Berg, Anna</creatorcontrib><creatorcontrib>Bartram, Claus R.</creatorcontrib><creatorcontrib>Basso, Giuseppe</creatorcontrib><creatorcontrib>Benoit, Yves C. M.</creatorcontrib><creatorcontrib>Biondi, Andrea</creatorcontrib><creatorcontrib>Debatin, Klaus-Michael</creatorcontrib><creatorcontrib>Haas, Oskar A.</creatorcontrib><creatorcontrib>Harbott, Jochen</creatorcontrib><creatorcontrib>Kamps, Willem A.</creatorcontrib><creatorcontrib>Köller, Ursula</creatorcontrib><creatorcontrib>Lampert, Fritz</creatorcontrib><creatorcontrib>Ludwig, Wolf-Dieter</creatorcontrib><creatorcontrib>Niemeyer, Charlotte M.</creatorcontrib><creatorcontrib>van Wering, Elisabeth R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Does-Van den Berg, Anna</au><au>Bartram, Claus R.</au><au>Basso, Giuseppe</au><au>Benoit, Yves C. M.</au><au>Biondi, Andrea</au><au>Debatin, Klaus-Michael</au><au>Haas, Oskar A.</au><au>Harbott, Jochen</au><au>Kamps, Willem A.</au><au>Köller, Ursula</au><au>Lampert, Fritz</au><au>Ludwig, Wolf-Dieter</au><au>Niemeyer, Charlotte M.</au><au>van Wering, Elisabeth R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1992</date><risdate>1992</risdate><volume>20</volume><issue>6</issue><spage>497</spage><epage>505</epage><pages>497-505</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><coden>MPONDB</coden><abstract>Minimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French‐American‐British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B‐ALL and T‐ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1435520</pmid><doi>10.1002/mpo.2950200603</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-1532 |
| ispartof | Medical and pediatric oncology, 1992, Vol.20 (6), p.497-505 |
| issn | 0098-1532 1096-911X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73317367 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | acute lymphoblastic leukemia BFM-family Biological and medical sciences Child children Chromosome Aberrations classification diagnosis Hematologic and hematopoietic diseases Humans Immunophenotyping International Cooperation Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Multicenter Studies as Topic - standards Neoplasm Recurrence, Local Neoplasm Staging Ploidies Precursor Cell Lymphoblastic Leukemia-Lymphoma - classification Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy |
| title | Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM family" cooperative group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A23%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Minimal%20requirements%20for%20the%20diagnosis,%20classification,%20and%20evaluation%20of%20the%20treatment%20of%20childhood%20acute%20lymphoblastic%20leukemia%20(ALL)%20in%20the%20%22BFM%20family%22%20cooperative%20group&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=van%20der%20Does-Van%20den%20Berg,%20Anna&rft.date=1992&rft.volume=20&rft.issue=6&rft.spage=497&rft.epage=505&rft.pages=497-505&rft.issn=0098-1532&rft.eissn=1096-911X&rft.coden=MPONDB&rft_id=info:doi/10.1002/mpo.2950200603&rft_dat=%3Cproquest_cross%3E73317367%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73317367&rft_id=info:pmid/1435520&rfr_iscdi=true |